The agency is still determining the impact of the privacy breach on other HHSC programs.
Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...
The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback